Indications And Dose
FRAGMIN ® Treatment of deep-vein thrombosis | Treatment of pulmonary embolism ▶BY SUBCUTANEOUS INJECTION ▶Adult: 200 units/kg daily (max. per dose 18 000 units) until adequate oral anticoagulation with vitamin K antagonist established (at least 5 days of combined treatment is usually required) Treatment of deep-vein thrombosis (in patients at increased risk of haemorrhage) | Treatment of pulmonary embolism (in patients at increase risk of haemorrhage) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 100 units/kg twice daily until adequate oral anticoagulation with vitamin K antagonist established (at least 5 days of combined treatment is usually required) Unstable coronary artery disease ▶BY SUBCUTANEOUS INJECTION ▶Adult: 120 units/kg every 12 hours (max. per dose 10 000 units twice daily) for 5–8 days Prevention of clotting in extracorporeal circuits ▶TO THE DEVICE AS A FLUSH ▶Adult: (consult product literature) FRAGMIN ® GRADUATED SYRINGES Unstable coronary artery disease (including non-ST- segment-elevation myocardial infarction) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 120 units/kg every 12 hours (max. per dose 10 000 units twice daily) for up to 8 days Patients with unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction) awaiting angiography or revascularisation and having already had 8 days treatment with dalteparin ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight up to 70 kg and male): 5000 units every 12 hours until the day of the procedure (max. 45 days). ▶Adult (body-weight up to 80 kg and female): 5000 units every 12 hours until the day of the procedure (max. 45 days). ▶Adult (body-weight 70 kg and above and male): 7500 units every 12 hours until the day of the procedure (max. 45 days). ▶Adult (body-weight 80 kg and above and female): 7500 units every 12 hours until the day of the procedure (max. 45 days). FRAGMIN ® SINGLE-DOSE SYRINGES Prophylaxis of deep-vein thrombosis in surgical patients— moderate risk ▶BY SUBCUTANEOUS INJECTION ▶Adult: Initially 2500 units for 1 dose, dose to be given 1–2 hours before surgery, then 2500 units every 24 hours Prophylaxis of deep-vein thrombosis in surgical patients— high risk ▶BY SUBCUTANEOUS INJECTION ▶Adult: Initially 2500 units for 1 dose, dose to be administered 1–2 hours before surgery, followed by 2500 units after 8–12 hours, then 5000 units every 24 hours, alternatively initially 5000 units for 1 dose, dose to be given on the evening before surgery, followed by 5000 units after 24 hours, then 5000 units every 24 hours Prophylaxis of deep-vein thrombosis in medical patients ▶BY SUBCUTANEOUS INJECTION ▶Adult: 5000 units every 24 hours Treatment of deep-vein thrombosis | Treatment of pulmonary embolism ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight up to 46 kg): 7500 units once daily until adequate oral anticoagulation with vitamin K antagonist established (at least 5 days of combined treatment is usually required) ▶Adult (body-weight 46–56 kg): 10 000 units once daily until adequate oral anticoagulation with vitamin K antagonist established (at least 5 days of combined treatment is usually required) ▶Adult (body-weight 57–68 kg): 12 500 units once daily until adequate oral anticoagulation with vitamin K antagonist established (at least 5 days of combined treatment is usually required) ▶Adult (body-weight 69–82 kg): 15 000 units once daily until adequate oral anticoagulation with vitamin K antagonist established (at least 5 days of combined treatment is usually required) ▶Adult (body-weight 83 kg and above): 18 000 units once daily until adequate oral anticoagulation with vitamin K antagonist established (at least 5 days of combined treatment is usually required) Extended treatment of venous thromboembolism and prevention of recurrence in patients with solid tumours ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight 40–45 kg): 7500 units once daily for Cardiovascular system 30 days, then 7500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature ▶Adult (body-weight 46–56 kg): 10 000 units once daily for 30 days, then 7500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature ▶Adult (body-weight 57–68 kg): 12 500 units once daily for 30 days, then 10 000 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature ▶Adult (body-weight 69–82 kg): 15 000 units once daily for 30 days, then 12 500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature ▶Adult (body-weight 83–98 kg): 18 000 units once daily for 30 days, then 15 000 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature ▶Adult (body-weight 99 kg and above): 18 000 units once daily for 30 days, then 18 000 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature Treatment of venous thromboembolism in pregnancy ▶BY SUBCUTANEOUS INJECTION ▶Adult (body-weight up to 50 kg): 5000 units twice daily, use body-weight in early pregnancy to calculate the dose ▶Adult (body-weight 50–69 kg): 6000 units twice daily, use body-weight in early pregnancy to calculate the dose ▶Adult (body-weight 70–89 kg): 8000 units twice daily, use body-weight in early pregnancy to calculate the dose ▶Adult (body-weight 90 kg and above): 10 000 units twice daily, use body-weight in early pregnancy to calculate the dose l UNLICENSED USE Not licensed for treatment of venous thromboembolism in pregnancy.
PDF pages 162, 163